Which antidepressant has the lowest risk of causing excessive sweating?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Antidepressant with Lowest Sweating Risk

Bupropion is the antidepressant least likely to cause excessive sweating and should be your first choice when sweating is a concern. 1

Evidence-Based Ranking

Lowest Risk (Preferred Options)

  • Bupropion: No significant increase in hyperhidrosis risk compared to placebo (RR = 1.23,95% CI: 0.57-2.67) 1
  • Fluvoxamine: No significant increase in sweating risk (RR = 0.56,95% CI: 0.12-2.53) 1
  • Vortioxetine: No significant increase in sweating risk (RR = 1.35,95% CI: 0.79-2.33) 1
  • Mirtazapine: Not associated with sweating as a typical side effect 2

High Risk (Avoid if Sweating is a Concern)

  • SSRIs as a class: Sweating is explicitly listed as a typical side effect, with 3-fold increased risk (RR = 2.93,95% CI: 2.46-3.47) 2, 1
  • SNRIs: Similar high risk to SSRIs (RR = 3.17,95% CI: 2.63-3.82) 1
  • Tricyclic antidepressants: Associated with excessive sweating 3, 4

Clinical Reasoning

The 2017 meta-analysis of 76 trials involving 28,544 subjects provides the most comprehensive quantitative data on sweating risk 1. This study found that sweating risk is associated with dopamine transporter affinity, explaining why bupropion (which primarily affects dopamine and norepinephrine without significant serotonin effects) has minimal sweating risk.

Important caveat: While guidelines note that SSRIs commonly cause sweating 2, 5, they recommend selecting antidepressants based on adverse effect profiles, cost, and patient preferences 6. The 2008 American College of Physicians guideline emphasizes that all second-generation antidepressants have similar efficacy, so choosing based on side effect profile is appropriate 6.

Practical Algorithm

  1. First-line for sweating-sensitive patients: Start bupropion (avoid in seizure disorders or highly agitated patients) 2

  2. Alternative first-line options: Mirtazapine (good if insomnia or poor appetite present) or fluvoxamine 2, 1

  3. If already on an SSRI/SNRI with problematic sweating:

    • Switch to bupropion or mirtazapine 4
    • If switching is not feasible, consider adding mirtazapine (case reports show dose-dependent reduction in SSRI-induced sweating) 7
    • Alternative adjuncts: benztropine or cyproheptadine 4

  4. Dose considerations: Sweating risk with SSRIs/SNRIs is NOT dose-dependent, so dose reduction may not help 1

Critical pitfall: Do not assume all antidepressants cause equal sweating. The evidence clearly shows bupropion, fluvoxamine, vortioxetine, and mirtazapine have significantly lower sweating risk than SSRIs and SNRIs 1.

References

4
Research

Antidepressant-induced sweating.

The Annals of pharmacotherapy, 2005

7
Research

Mirtazapine in drug-induced excessive sweating.

European journal of clinical pharmacology, 2005

Related Questions

A patient on fluoxetine (Prozac) reports excessive sweating; how should this be managed?
How can I manage sweating caused by escitalopram (Lexapro) and stimulant medication?
What is the likely cause and management of nightly and four‑times‑weekly hyperhidrosis in a female patient taking escitalopram (Lexapro) 5 mg and mirtazapine 7.5 mg?
Do fluoxetine and buspirone cause hyperhidrosis (excessive sweating)?
Do selective serotonin reuptake inhibitors cause nocturnal hyperhidrosis, and what is the mechanism?
What are the management considerations for an adult with a chronic psychotic disorder, in remission from methamphetamine use for five years, who is taking lurasidone 120 mg daily, lisdexamfetamine (Vyvanse) 50 mg each morning, and newly added amantadine 100 mg daily?
What is the appropriate antibiotic regimen for a urinary tract infection caused by Klebsiella pneumoniae that is susceptible to nitrofurantoin, amoxicillin‑clavulanic acid, and trimethoprim‑sulfamethoxazole in a patient with normal renal function?
In an 87‑year‑old patient with an isolated elevation of serum free kappa light chain (initially 28.6 mg/L, decreasing to 23.4 mg/L on repeat) and normal serum protein electrophoresis, urine protein electrophoresis, and lambda light chains, what is the most likely diagnosis and how should this be managed?
Can measles rash involve the palms?
Is there any difference in efficacy or safety when timolol eye drops are administered during the day versus at night?
What is the appropriate management for a 63-year-old male with celiac disease and persistent iron‑deficiency anemia despite an intravenous iron infusion four months ago, given current labs of hemoglobin 13.8 g/dL, hematocrit 41.6 %, red cell distribution width 15.9 %, serum iron 55 µg/dL, transferrin 243 mg/dL, total iron‑binding capacity 304 µg/dL, iron saturation 18 % and ferritin 11 ng/mL?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.